Objectives
At the conclusion, the participant should be able to:
IDENTIFY conditions
that may emergently threaten pregnancy,
IDENTIFY obstetric
conditions that warrant emergent interventions,
DESCRIBE the
appropriate obstetric interventions for emergencies.
IDENTIFY the potential complications of Magnesium
Sulfate,
DESCRIBE the
importance of dosage in determining the effectiveness of Magnesium Sulfate,
COMPARE effectiveness
of Magnesium Sulfate to other tocolytics
DISCUSS maternal genetic disorders and
considerations for pregnancy,
REVIEW preconception
recommendations for women with specific health issues,
DISCUSS current ACOG
guidelines regarding preconception counseling.
IDENTIFY risk factors for HIV and Hepatitis A, B,
C, D, and E.
IDENTIFY Perinatal
complications involving Hepatitis and HIV,
IDENTIFY adverse
Perinatal outcomes associated with pyelonephritis
RECOGNIZE the
limitations and benefits of fetal monitoring,
DESCRIBE fetal heart
rate tracings that require emergent interventions,
RECOGNIZE the
progression of changes on the fetal heart rate monitor that are associated with
progressive asphyxia.
IDENTIFY
common fetal anomalies with ultrasound,
IDENTIFY unusual fetal
anomalies and their clinical significance,
DESCRIBE
and
IDENTIFY evaluation of
common fetal anomalies
IDENTIFY
why DVT is a healthcare issue in Obstetrics,
DEFINE
the guidelines/recommendation concerning prevention
of DVT in the obstetric population,
DESCRIBE how
Implementation of a DVT program can reduce the risk of DVT in our at risk
population
IDENTIFY
adverse maternal outcomes associated with obesity,
IDENTIFY adverse
Perinatal outcomes associated with obesity,
IDENTIFY changes in
management of pregnancies complicated by a history of gastric bypass
DISCUSS recent ACOG recommendations regarding
aneuploidy screening,
REVIEW various
screening options,
DISCUSS counseling
issues related to aneuploidy screening
IDENTIFY
the risks and benefits of certain drugs during
pregnancy,
IDENTIFY specific side
effects of some commonly used drugs in pregnancy,
DESCRIBE
the basic concepts of risk assessing drug use
during pregnancy.
MFM home / Objectives\ Agenda / Faculty \ Accreditation / Location \ Registration / Other Seminars \ MECOP Home /